Physician profile
Mark Sarnak
NPI 1982641502
$35,731.22
in general payments reported to CMS, 2019-2025
9 companies · $5,838 in 2025
The $5,838 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,464 · 2020: $5,400 · 2021: $299 · 2022: $2,195 · 2023: $12K · 2024: $5,729 · 2025: $5,838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Travel and Lodging: $372 · Food and Beverage: $359 · Education: $31.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,610.00 |
| Travel and Lodging | $371.94 |
| Food and Beverage | $359.44 |
| Education | $31.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $12,960.00 | 2020-2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $9,176.08 | 2022-2023 | |
| Astrazeneca Uk Limited | $7,000.00 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $4,698.25 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,250.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $315.91 | 2023 | |
| Fresenius USA Marketing, INC. | $249.00 | 2021 | |
| Corcept Therapeutics | $50.00 | 2021 | |
| Travere Therapeutics, INC. | $31.98 | 2024-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Sarnak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.